388. Sigurdardottir G.R., Nilsson C., Odin P., et al. Cardiovascular effects of domperidone in patients with Parkinson's disease treated with apomorphine. Acta neurologica Scandinavica. 2001;104(2):92–96.
389. Proulx M., de Courval F.P., Wiseman M., et al. Salivary production in Parkinson’s Disease. Movement Disorders. 2005; 20: 204-207
390. van Wamelen D.J., Leta V., Johnson J., et al. Drooling in Parkinson's Disease: Prevalence and Progression from the Non-motor International Longitudinal Study. Dysphagia. 2020; 35(6):955-961.
391. Nobrega A.C., Rodrigues B., Torres A.C., et al. Is drooling secondary to a swallowing disorder in patients with Parkinson’s disease? Parkinsonism Relat Disord. 2008; 14(3): 243-245.
392. Chen Z., Li G., Liu J. Autonomic dysfunction in Parkinson's disease: Implications for pathophysiology, diagnosis, and treatment. Neurobiol Dis. 2020; 134:104700.
393. South A. R., Somers S. M., Jog M. S. Gum chewing improves swallow frequency and latency in Parkinson patients: a preliminary study. Neurology. 2010; 15:1198–1202.
394. Zhang Z., Chen S.D. Autonomic Dysfunctions in Parkinson’s Disease: Prevalence, Clinical Characteristics, Potential Diagnostic Markers, and Treatment. Hindawi Parkinson’s Disease. 2020; ID 8740732, 10 p. https://doi.org/10.1155/2020/8740732.
395. Davydov L., Botts S.R. Clozapine-induced hypersalivation Ann Pharmacother. 2000; 34: 662-665.
396. Chatelut E., Rispail Y., Berlan M., et al. Yohimbine increases human salivary secretion Br J Clin Pharmacol. 1989; 28:366-368.
397. Srivanitchapoom P., Pandey S., Hallett M. Drooling in Parkinson's disease: A review. Parkinsonism & Related Disorders. 2014; 20(Issue 11):1109-1118.
398. Egevad, G., Petkova, V.Y., et al. Sialorrhea in patients with Parkinson's disease: safety and administration of botulinum neurotoxin. J. Parkinsons Dis. 2014; 4, 321–326.
399. Ruiz-Roca J.A., Pons-Fuster E., Lopez-Jornet P. Effectiveness of the Botulinum Toxin for Treating Sialorrhea in Patients with Parkinson's Disease: A Systematic Review. J Clin Med. 2019;8(3):317.
400. Sridharan K., Sivaramakrishnan G. Pharmacological interventions for treating sialorrhea associated with neurological disorders: A mixed treatment network metaanalysis of randomized controlled trials. J. Clin. Neurosci. 2018;51:12–17.
401. Chou K. L., Evatt M., Hinson V., et al. Sialorrhea in Parkinson’s disease: a review. Movement Disorders. 2007; 16: 2306–2313.
402. Camilleri M., Parkman H.P., Shafi M.A., et al. American College of G. Clinical guideline: management of gastroparesis. Am J Gastroenterol.2013; 108(1):18–37.
403. Palma J.A., Kaufmann H. Treatment of autonomic dysfunction in Parkinson disease and other synucleinopathies.Mov Disord. 2018;33(3):372-390.
404. Soykan I., Sarosiek I., Shifflett J., et al. Effect of chronic oral domperidone therapy on gastrointestinal symptoms and gastric emptying in patients with Parkinson's disease. Movement disorders: official journal of the Movement Disorder Society. 1997; 12(6): 952–957.
405. Agid Y., Pollak P., Bonnet A.M., et al. Bromocriptine associated with a peripheral dopamine blocking agent in treatment of Parkinson's disease. Lancet. 1979; 1:570–572.
406. Magnifico F., Pierangeli G., Barletta G., et al. The cardiovascular effects of metoclopramide in multiple system atrophy and pure autonomic failure. Clinical autonomic research: official journal of the Clinical Autonomic Research Society.2001; 11(3):163–168.
407. Ashraf W., Pfeiffer R.F., Park F., et al. Constipation in Parkinson's disease: objective assessment and response to psyllium. Mov Disord 1997; 12: 946– 951.
408. Perez-Lloret S., Rey M.V., Pavy-Le Traon A., et al. Emerging drugs for autonomic dysfunction in Parkinson's disease. Expert Opin Emerg Drugs. 2013; 18(1):39-53.
409. Barichella M., Pacchetti C., Bolliri C., et al. Probiotics and prebiotic fiber for constipation associated with Parkinson disease: An RCT.Neurology. 2016; 87(12):1274–1280
410. Zangaglia R., Martignoni E., Glorioso M., et al. Macrogol for the treatment of constipation in Parkinson's disease. A randomized placebo‐controlled study. Mov Disord. 2007; 22: 1239– 1244.
411. Ondo W.G., Kenney C., Sullivan K., et al. Placebo-controlled trial of lubiprostone for constipation associated with Parkinson disease. Neurology. 2012;78(21):1650–1654.
412. Poirier A.A., Aubé B., Côté M., et al. Gastrointestinal Dysfunctions in Parkinson’s Disease: Symptoms and Treatments. Parkinson’s Disease. 2016; ID 6762528, 23 p.
413. Batla A., Tayim N., Pakzad M., et al. Treatment Options for Urogenital Dysfunction in Parkinson's Disease. Curr Treat Options Neurol. 2016; 18(10):45.
414. Griffiths D.J., McCracken P.N., Harrison G.M., et al. Relationship of fluid intake to voluntary micturition and urinary incontinence in geriatric patients. Neurourol Urodyn.1993;12(1):1–7.
415. Aranda B., Cramer P. Effects of apomorphine and L‐dopa on the parkinsonian bladder.Neurourol Urodyn. 1993; 12: 203– 209.
416. Benson G.S., Raezer D.M., Anderson J.R., et al. Effect of levodopa on urinary bladder. Urology 1976; 7: 24– 28.
417. Winge K., Werdelin L.M., Nielsen K.K., et al. Effects of dopaminergic treatment on bladder function in Parkinson's disease. Neurourol Urodyn. 2004; 23: 689– 696.
418. Sakakibara, R., Panicker, J., Finazzi-Agro, E., et al. Parkinson's Disease Subcomittee, T.N.P.C.i.T.I.C.S,. A guideline for the management of bladder dysfunction in Parkinson's disease and other gait disorders. Neurourol. Urodynam. 2016: 35, 551–563.
419. Christmas T.J., Kempster P.A., Chapple C.R., et al. Role of subcutaneous apomorphine in parkinsonian voiding dysfunction. Lancet 1988; 2:1451– 1453.
420. Brusa L., Petta F., Farullo G., et al. Rotigotine Effects on Bladder Function in Patients with Parkinson's Disease. Mov Disord Clin Pract. 2017; 4(4):586-589.